141
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:July 30, 2019Completed
Refractory Multiple Myeloma: 1441 Clinical Trials, Page 15 of 145
Hide Studies Not Open or Pending
142
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:October 18, 2022Completed
143
Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:February 2, 2022Terminated
144
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:July 17, 2019Completed
145
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple Myeloma in RelapseLast Updated:September 5, 2021Completed
146
Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple Myeloma and Plasma Cell NeoplasmLast Updated:August 29, 2013Completed
147
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:January 6, 2023Completed
148
Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:March 2, 2022Recruiting
149
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:August 24, 2022Completed
150
Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed Multiple Myeloma; Refractory Multiple MyelomaLast Updated:July 7, 2022Withdrawn